Parkinson disease: Adjunctive entacapone therapy increases risk of dyskinesia

Nature Reviews Neurology

Volumn 6, Issue 11, 2010, Pages 590-591

  Sampaio, Cristina ^a   Ferreira, Joaquim J ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA;

ADJUVANT THERAPY; ADVERSE OUTCOME; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TREATMENT FAILURE; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; NERVE STIMULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION;

ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; NEUROLOGIC EXAMINATION; NITRILES; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE;

EID: 78149398961     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.158     Document Type: Short Survey

References (10)

1. Grace, A. A. & Bunney, B. s. The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4, 2866-2876 (1984).
2. smith, L. A. et al. Multiple small doses of levodopa plus entacapone produces continuous dopaminergic stimulation and reduces dyskinesia induction in MPTP treated drug naive primates. Mov. Disord. 20, 306-314 (2005).
3. stocchi, F. et al. initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the sTRiDe-PD study. Ann. Neurol. 68, 18-27 (2010).
4. Rascol, O. et al. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342, 1484-1491 (2000).
5. Parkinson study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284, 1931-1938 (2000).
6. Kuoppamäki, M. et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur. J. Clin. Pharmacol. 65, 443-455 (2009).
7. Heikkinen, H. et al. entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose. Br. J. Clin. Pharmacol. 54, 363-371 (2002).
8. Block, G., Liss, C., Reines, s., irr, J. & nibbelink, D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First study Group. Eur. Neurol. 37, 23-27 (1997).
9. Dupont, e. et al. sustained-release Madopar HBs compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand. 93, 14-20 (1996).
10. Mouradian, M. M., Heuser, i. J., Baronti, F. & Chase, T. n. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27, 18-23 (1990).